Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Acorda Therapeutics Inc ACORQ

Acorda Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. The Company markets Inbrija (levodopa inhalation powder), which is approved in the United States for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson’s disease treated with carbidopa/levodopa. Inbrija is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor, such as phenelzine or tranylcypromine within the last two weeks. Inbrija utilizes its ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. ARCUS is a dry-powder pulmonary drug delivery technology. It also markets the branded AMPYRA (dalfampridine) extended-release tablets, 10 mg, to improve walking in adults with multiple sclerosis. Ampyra is marketed as Fampyra outside the United States by Biogen International GmbH.


OTCPK:ACORQ - Post by User

Post by Iseneschalon Oct 10, 2022 9:43am
75 Views
Post# 35015555

ACOR ..... Go tell the Directors to go Sh8t in a river

ACOR ..... Go tell the Directors to go Sh8t in a riverThey are jerking this all over the place.... I say it's all a bunch of Bull sh8t.... I still don't have a position.

Maddapakkas......want all of you out ; )

Acorda Therapeutics Withdraws Proposal to Increase Authorized Shares from Special Meeting of Stockholders

2022-10-10 03:30 ET - News Release

 


PEARL RIVER, N.Y. -- (Business Wire)

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the company has withdrawn Proposal One, a request to increase the number of authorized shares of Acorda stock, from the ballot for the Special Meeting of Stockholders scheduled for November 4, 2022.

Proposal Two, authorization of a Reverse Stock Split, remains on the ballot. This proposal would give Acorda's Board of Directors the ability to implement a reverse stock split of Acorda's stock. Proposal Three, the Adjournment Proposal, to allow the Company to adjourn and reconvene the Special Meeting to have additional time to solicit proxies, will also remain on the ballot.

"We have concluded that it is not in the best interests of shareholders to request an increase in authorized shares at this time," said Ron Cohen, M.D., Acorda's President and Chief Executive Officer. "However, the proposal to implement a reverse split of Acorda's stock remains critical to ensure that we can get the stock price above $1.00, which would prevent the company from being delisted by Nasdaq. If that were to occur, we could be in default on our obligations to our debtholders and may be required to declare bankruptcy or liquidate, which would be adverse to the interests of shareholders and patients. It's important to note that a reverse split will not change the value or ownership interest of any shareholder's position in Acorda, and the Board of Directors urges shareholders to vote 'For' that proposal."

<< Previous
Bullboard Posts
Next >>